CKS is no longer commissioned by the National Institute for Health and Clinical Excellence (NICE). NICE remains committed to providing a replacement service for CKS and is currently reviewing its options. In the meantime, although CKS content is now not being maintained, it still remains relevant and will continue to be made available. CKS content was generated under a programme of topic creation and update. To check if the topic you are viewing is current or out of date, please refer to the topic publication details by clicking on the 'How up-to-date is this topic?' link in the left hand menu on individual topic pages.
Lipid modification - primary and secondary CVD prevention - Management
Which first-line lipid modification therapy is recommended for secondary prevention?
- Prescribe a statin, unless this is contraindicated.
- Simvastatin 40 mg daily is the first-line choice.
- Consider a lower dose of simvastatin or an alternative statin (e.g. pravastatin 40 mg daily) if there are potential drug interactions or simvastatin 40 mg is contraindicated.
- Higher intensity statin therapy (simvastatin 80 mg or atorvastatin 80 mg) should only be considered first-line for people with acute coronary syndrome. Treatment should be initiated in secondary care.
In depth
© NHS Institute for Innovation and Improvement